However, an elevated level of thyroid antibodies found at the beginning of the treatment is a risk factor of both the development as well as exacerbation of thyroid disorders in the course of anti-PD-1 treatment [19,21,40,75,81,82]. The gene discussed is PDCD1; the disease is thyroid gland disorder.